Key management strategies include anti-VEGF therapies, which are considered the primary treatment option for DME due to their effectiveness in inhibiting VEGF, a crucial factor contributing to the development of DME and proliferative diabetic retinopathy [23]. Here, VEGFA is linked to proliferative diabetic retinopathy.